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Although motor deﬁcits aﬀect patients with Alzheimer’s disease (AD) only at later stages, recent studies demonstrated that
primary motor cortex is precociously aﬀected by neuronal degeneration. It is conceivable that neuronal loss is compensated by
reorganization of the neural circuitries, thereby maintaining motor performances in daily living. Eﬀectively several transcranial
magnetic stimulation (TMS) studies have demonstrated that cortical excitability is enhanced in AD and primary motor cortex
presents functional reorganization. Although the best hypothesis for the pathogenesis of AD remains the degeneration of cho-
linergic neurons in speciﬁc regions of the basal forebrain, the application of speciﬁc TMS protocols pointed out a role of other
neurotransmitters.ThepresentpaperprovidesaperspectiveoftheTMStechniquesusedtostudyneurophysiologicalaspectsofAD
showing also that, based on diﬀerent patterns of cortical excitability, TMS may be useful in discriminating between physiological
and pathological brain aging at least at the group level. Moreover repetitive TMS might become useful in the rehabilitation of AD
patients. Finally integrated approaches utilizing TMS together with others neuro-physiological techniques, such as high-density
EEG, and structural and functional imaging as well as biological markers are proposed as promising tool for large-scale, low-cost,
and noninvasive evaluation of at-risk populations.
1.Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder cli-
nically characterized by a progressive cognitive decline that
aﬀects memory and other cognitive functions, as well as
mood and behavior [1]. It is the most common type of de-
mentia and nowadays it aﬀects more than 35 million people
all over the world. The disease is characterized by extra-
cellular formation of Aβ amyloid plaques and intracellular
deposition of neuroﬁbrillary tangles in speciﬁc cortical areas;
this process leads to loss of neurons and white matter,
amyloid angiopathy, inﬂammation, and oxidative damage
[2]. Transcranial magnetic stimulation (TMS) is a safe,
noninvasive and painless technique today widely employed
to explore brain functions [3, 4]. From about 15 years, it
provides a valuable tool for studying the pathophysiology of
Alzheimer’s disease. This paper intends to review the most
relevant studies in the literature in order to provide to the
reader a clear picture of what we have learned by using TMS
in the study of AD. A PubMed-based literature review of
English-language studies was performed to acquire publica-
tions on AD and TMS. Key search words were “dementia,
Alzheimer’s disease, transcranial magnetic stimulation, and
motor cortex excitability.”
This work is schematically divided in to several sections:
after the introduction, in Section 2 we brieﬂy discuss basic
principles of TMS and some types of paradigms used by
researchers in studying AD patients; in Section 3 we explain
why TMS is important for studying AD pathophysiology
and what are the main AD alterations highlighted with this
neurophysiological technique; in Section 4 we brieﬂy intro-
duce studies that used TMS to make diﬀerential diagnosis2 International Journal of Alzheimer’s Disease
of dementia; in Section 5 we discuss TMS employment as
a treatment tool and in Section 6 we provide concluding
remarks and topics of future research.
2. TMS
Transcranial magnetic stimulation (TMS) is a safe, non-
invasive, and painless technique today widely employed in
studies designed to explore brain functions [3, 4]. It was in-
troduced by Barker and colleagues in 1985, inspired by
transcranial electric stimulation studies. In TMS short cur-
rent pulses are driven through a coil positioned on the scalp
of the subject [6]. The transient magnetic ﬁeld generated in
the brain produces an electrical current able to depolarize
the cell membrane, resulting in opening of voltage-gated ion
channelsandconsequentlygivingrisetotheactionpotential.
The electric ﬁeld induced by TMS depends on the position
and orientation of the coil over the head of the subject and
also by structural anatomical features and by the local con-
ductivityofthescalpitself[7].Diﬀerenttypesofstimulation,
declined in several type of paradigms, are currently possible
(e.g., single pulse, paired-pulse, repetitive): we will focus on
those more widely used in studying Alzheimer’s disease.
2.1. Single Pulse. Applying a single TMS pulse over primary
motor area, a series of epidurally recordable corticospinal
volleys are generated which reﬂect the transsynaptic activa-
tion of superﬁcial cortical neurons. Volley’s temporal sum-
mation at the spinal motoneuron level elicit a motor evoked
potential (MEP) in contralateral target muscles [8]. This ap-
proachisusefultostudythediseaseprocessesortheneuroac-
tivedrugs[9–12]thataﬀectregulatorymechanismofcortical
excitability [13]. Single TMS pulses are also very useful to
track plastic changes which originate from physiological and
pathological manipulations involving the motor system and
can be used for mapping motor cortical outputs. Cortical
mapping procedures, with single TMS pulses focally applied
on several scalp positions overlying the motor cortex, take
into account the number of cortical sites eliciting MEPs in a
target muscle and its “center of gravity” (COG, [9, 10]). The
location of the COG of the MEP map corresponds to the sc-
alp location at which the largest number of the most ex-
citable corticospinal neurons can be stimulated. Therefore,
changes in the COG are considered able to indicate true
changes in the topographical organization of motor cortex
representations.
2.2. Paired-Pulse (SICI and ICF, SAI). TMS paired-pulse
(ppTMS) protocols consist in the erogation of two individ-
ual diﬀerent kinds of stimuli separated by a predetermin-
ed interval of time (interstimulus interval -ISI-). In a well-
known paradigm [12, 15] able to test intracortical inhibi-
tory/facilitatorybalance,asubthresholdmagneticcondition-
ing stimulus (S1) is followed by a suprathreshold magnetic
test stimulus (S2) delivered on the same target area through
the same coil. The eﬀect of S1 on the size of control MEP
is thought to originate at the cortical level [14, 16, 17]. It
is in fact known that a supra-threshold stimulus determines
a corticospinal output leading to a MEP, while a sub-thre-
shold stimulus only excites local, cortical interneurons [18].
Thus, by combining a sub-threshold pulse with a supra-
threshold pulse one can assess the eﬀects of inter-neurons on
cortical output [19, 20]. The test responses are inhibited at
interstimulus intervals (ISIs) of 1–5ms and are facilitated at
ISIs of 8–30ms; these phenomena are referred as short intra-
cortical inhibition (SICI) and intracortical facilitation (ICF).
Based on the time course of cortical inhibition and facili-
tation and on results of pharmacological manipulations dur-
ing ppTMS, several authors have suggested that SICI is med-
iated by GABA-A receptors [21] whereas ICF is mediated
by glutamatergic N-methyl-D-aspartate (NMDA) receptors,
[19, 20]. The balance between SICI and ICF is altered in se-
veral neurological conditions showing abnormal cortical ex-
citability [22, 23].
Another paradigm, widely used in AD, to study intracor-
ticalinhibitorymechanismsistheshort-latencyaﬀerentinhi-
bition (SAI). This approach consists of a conditioning elec-
tricstimulationappliedonthemediannerveatthewristpre-
ceding a contralateral TMS test pulse by 20–25ms, a timing
compatible to the activation of the primary sensori-motor
cortex.TheresultingMEPsareinhibitedwithrespecttothose
evoked by the test pulse alone. The origin of this phenom-
enon is cortical [24–26] and probably it depends on the cen-
tral cholinergic activity; Di Lazzaro and colleagues in fact
clearly demonstrated that SAI can be abolished by scopo-
lamine, a muscarinic antagonist [27].
2.3.RepetitiveTMS. RepetitiveTMS(rTMS)consistofsingle
TMS pulses delivered in trains with a constant frequency
and intensity for a given time. Repetitive TMS is capable to
temporarily modify the function of the underlying cortical
area because rTMS may exert excitatory or inhibitory actions
on underling cortical activity, depending on TMS parameter
used, as well as on the task at hand. An important feature of
rTMS is the capacity, depending on the frequency of applica-
tion, to increase or decrease the level of cortical excitability.
This is the basis for the reported clinical beneﬁts in diseases
linked to brain excitability dysfunctions and the reason why
this technique is increasingly used with therapeutic and
rehabilitative functions [28, 29].
3. TMS for Studying ADPathophysiology
Neurophysiological aspects usually studied in Alzheimer’s
disease by means of TMS are alteration of motor cortex ex-
citability and cortical reorganization of motor output. TMS
studies have in fact clearly demonstrated the existence of
cortical hyperecitability and subclinical motor cortical reor-
ganization mostly in the early stages of AD.
The cortical hyperexcitability is believed to be a compen-
satory mechanism to execute voluntary movements [5], des-
pite the progressive impairment of associative cortical areas.
At present, it is not clear if these motor cortex excitability
changes might be the expression of an involvement of intra-
cortical excitatory glutamatergic circuits or an impairment
of cholinergic and/or gabaergic activity [5]. In fact, althoughInternational Journal of Alzheimer’s Disease 3
the best hypothesis for the pathogenesis of AD remains the
degenerationofcholinergicneuronsinspeciﬁcregionsofthe
basal forebrain, the application of speciﬁc TMS protocols,
such as the paired-pulse TMS (ppTMS) and the study of the
short-latency aﬀerent inhibition (SAI; [30–32]), points out
the role of other neurotransmitters, such as γ-aminobutyric
acid (GABA), glutamate, and dopamine [33, 34].
3.1. Alteration of Motor Cortex Excitability in Alzheimer’s
Disease. E v enthoughTMSevaluationsinADha v enotyield-
ed absolutely converging ﬁndings, recent studies, but one
[35], strongly support the hypothesis of early motor cortex
globalhyperexcitabilityinAD[5],opposedtotheprogressive
hypoexcitability to TMS normally found with aging [36, 37].
Most of these studies showed that resting motor threshold
(rMT)isgenerallyreducedinADandinsubcorticalischemic
vascular dementia (VaD) compared to healthy age-matched
controls [18, 30, 32, 38–42]; however several other reports
have not found reduction of motor thresholds [5, 43–45].
To date it is not yet possible to give an univocal patho-
physiological interpretation of the hyperexcitability, however
it could be determined mainly by two diﬀerent mechanisms:
(i) increase of excitability of the intracortical excitatory
circuits;
(ii) impairmentofintracorticalinhibitorycircuitsresulting
in a disinhibition of the motor cortex.
As the main excitatory neurotransmitter in the brain is glu-
tamate, the ﬁrst mechanism would imply an involvement
of glutamatergic transmission in AD. Indeed, several studies
suggest that abnormalities of glutamatergic neurotransmis-
sion might play an important role in AD, and the glutama-
tergic hypothesis of AD has been proposed as an auxiliary
mechanism to the cholinergic hypothesis [5]; this would
be due to an imbalance between non-NMDA and NMDA
neurotransmission [5, 46–50].
However, the hypothesis of impairment of intracortical
inhibitory circuits leading to disinhibition of the motor cor-
tex in AD should also be taken carefully into consideration
because several recent studies have demonstrated an abnor-
mality of two inhibitory mechanisms accessible via TMS in
patientswithAD,thatis,SICIandSAI,respectivelymediated
by GABA-A receptors and cholinergic neurons activities.
Liepert and colleagues in 2001 used ppTMS according to
Kujiraiandcolleagues[15]inmildlytomoderatelydemented
AD patients. They found a reduced SICI compared to an
age-matched control group and a correlation between the
amount of disinhibition and the severity of dementia. Later,
in 2004, Pierantozzi and colleagues applied the same ppTMS
protocol in two groups of early-onset demented patients
with a neuropsychological proﬁle suggestive of AD and
frontotemporal dementia (FTD). They found a signiﬁcant
reduction of MEPs inhibition at ISI 2-3ms in early-onset
AD patients but not in controls and in FTD patients and
speculated that these changes may be ascribed, at least in
part, to an impaired endogenous cholinergic transmission
(see also [44]) as they might be reversed by middle-term
treatment with galantamine and other acetylcholinesterase
inhibitors [30, 43, 44]. In 2010 also Olazar´ an and colleagues
used the same ppTMS protocol in eleven patients with
mild cognitive impairment (MCI) that converted to AD and
12elderlycontrolsubjects.CognitiveassessmentandppTMS
were performed at baseline in the two groups and after 4
and 21 months of treatment with donepezil in the AD group
and ICF and SICI were found reduced in AD patients. How-
ever, there was high interindividual variability, and statistical
signiﬁcance was only attained at a 2-ms interstimulus inter-
val(ISI).Atrendtowardsrecoveryof2-msSICIwasobserved
after treatment with donepezil. Baseline cortical excitability
at 300ms was associated with better cognitive performance
in AD patients. Anyway, although the SICI is considered to
be mediated by GABA-A receptors [21], to date it is not
clear if the SICI impairment observed in AD patients is really
an expression of an involvement of GABAergic activity [51]
as biochemical investigations of biopsy brain tissue from
patients in the early phases of AD have not shown signiﬁcant
alterationsintheconcentrationofGABAandnodisturbance
of GABA transporters [52, 53].
ConvergingevidencealsosuggeststhatSAI,aninhibitory
phenomenon [24, 26, 54] considered as a putative marker of
central cholinergic activity, is reduced in AD and that AChEI
(acetylcholinesteraseinhibitors)therapycanrescueit[18,32,
55]pointingoutthefactthatprobablythecentralcholinergic
dysfunctionoccursinearlystagesofAlzheimer’sdisease[55].
However also other neurotransmitters were recently claimed
to be involved in AD; for example, recently Martorana and
colleagues[56],totestwhethercholinergicdisfunctioncould
be modiﬁed by dopamine, designed a neurophysiological
protocol consisting of the study of SAI before and after a
single L-Dopa administration in AD patients and in healthy
subjects. They observed that SAI was reduced in AD pa-
tients with respect to normal subjects, and that L-dopa
administration was able to restore SAI-induced modiﬁcation
only in AD. They explained these data with a relationship
between acetylcholine and dopamine systems.
Finally, very recently we explored changes in cortical ex-
citability and reorganization in AD during long-term AchEIs
therapy [14, 57]. We compared motor cortex functionality in
10 AD patients before and after one year of AchEIs therapy
and we found the examined parameters of motor cortex
physiology unchanged in patients with stabilized cognitive
performance during the therapy (Tables 1 and 2). Therefore,
thought the study was performed in a limited number of
patients, we suggested that serial TMS analysis might be a
useful, non-invasive and low-cost method to monitor rate of
change in motor cortex hyperexcitability in AD, as well as
AchEI CNS bioavailability and long-term pharmacological
response. This idea is also supported by other experiments
using the evaluation of SAI for the assessment of response to
treatment [18, 31].
In conclusion, clinical and neuropsychological assess-
ment are current standards to evaluate response to therapy
andtheyarewellvalidated,buttheyaresomewhatdependent
on examiner’s expertise and, most of all, on patient’s moti-
vation. TMS could be helpful in reducing interindividual
variability and achieving a more direct measure of disease
progression. To date there are not univocal explanations of4 International Journal of Alzheimer’s Disease
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Figure 1: ADM: Abductor Digiti Minimi Muscle, ECD: Extensor Digitorum Communis Muscle. This graph shows that the map centre of
gravity of the two muscles considered separately is in controls widely distributed around to hot-spot, while in patients it is evidently located
anteromedial to it (modiﬁed from [5]).
Table 1: Mini mental state evaluation trend over two years in patients examined. T1: basal evaluation, T2: 1 year after AchE-ib treatment, T3:
1 year after the last TMS session, DS: standard deviation. Patients, both as a group and as individual cases, could be considered cognitively
stabilized at T2 and at T3 and formed an homogeneous group (modiﬁed from [14]).
PATIENT MMSE at T1 MMSE at T2
Diﬀerence
between MMSE
at T1 and T2
MMSE at T3
Diﬀerence
between MMSE
at T1 and T3
Total diﬀerence
12 3 2 21 2 2 0 1
22 3 2 12 2 0 1 3
32 0 2 00 1 9 1 1
42 1 2 01 1 8 2 3
52 1 2 01 1 9 1 2
62 1 2 01 1 8 2 3
72 3 2 12 2 0 1 3
81 9 1 81 1 6 2 3
91 9 1 81 1 6 2 3
10 23 23 0 22 1 1
1 1.3 2.18 Media
0.67 0.67 0.95 DS
TMS ﬁndings because the pathophysiology of AD refers to a
complex involvement of diﬀerent neurotransmitter systems
in many brain areas. For example GABAergic dysfunctions
revealed by paired-pulse TMS studies, could represent an
epiphenomenon of the complex cortical excitability balance.
This equilibrium is probably related to age, disease duration,
and degree of cognitive impairment. In other words AD
should be viewed as a pathological mosaic composed of
numerous facets, in which the neurotransmitter question is
only a piece of the problem.
3.2. Cortical Reorganization of Motor Output in AD. Motor
symptoms are considered late events in the natural history of
AD and their early occurrence makes the diagnosis less likely
[5]. The delayed involvement of the motor system has been
variably explained A smaller burden of neuropathologicalInternational Journal of Alzheimer’s Disease 5
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Figure 2: In AD patients is present a signiﬁcant frontomedial shift of the center of gravity of MI output. In fact, comparing AD (a) and
Controls (b) cortical maps how the hot-spot (red area) is not coincident with the center of gravity (yellow area) is evident (modiﬁed from
[5]).
Table 2: Motor cortex excitability parameters trend in patients examined. T1: basal evaluation, T2: 1 year after AchE-ib treatment, ADM:
Abductor Digiti Minimi Muscle, ECD: Extensor Digitorum Communis Muscle, SD: standard deviation. The table shows the AchEI therapy
eﬀect was not signiﬁcantly impacting on TMS parameters (Pillai’s trace =.996; F(5,5) = 2.440; P = .175). Consistently, looking at single
measures, the authors did not ﬁnd any signiﬁcant change (P = .154 for threshold, P = .416 for ADM area, P = .484 for ECD area, P = .682
for ADM volume, P = .368 for ECD volume) (modiﬁed from [14]).
TMS Parameter Hemisphere
Time
T1 T2
Mean SD Mean SD
Threshold (%) Right 40.8 5.8 38.7 6.8
Left 39.6 4.9 37.4 5.6
Area ADM (N) Right 5.3 2.5 4.9 2.4
Left 5.4 3.5 4.4 3.5
Area ECD (N) Right 5.7 2.6 5.3 2.5
Left 6.1 4.3 5.2 3.5
Volume ADM (microV) Right 26.8 12.9 27.0 15.1
Left 29.4 18.9 25.8 19.5
Volume ECD (microV) Right 33.3 15.6 29.7 15.8
Left 38.4 27.6 31.9 21.0
changes in the motor cortices, compared with other brain
areas, a rich dendritic arborization and progressive neuronal
reorganization compensatory for neural loss, have all been
hypothesized. Recent neuropathological studies, though,
have shown that the density of neuroﬁbrillary tangles (NFTs)
and senile plaques (SPs) in the motor cortex is comparable
to that of other cortices generally considered more speciﬁc
targets for AD pathology, such as the enthorinal cortex, the
hippocampus, and the associative parietal and frontal areas
[58]. Despite early modiﬁcations of motor cortex seem to be
part of the neurodegenerative process in AD [58], the lack
ofearlyclinicalmanifestationsmightbeascribedtoitsability
to reorganize via alternative circuits, due to its natural dis-
tributed network with multiple representations of the motor
maps [59]. The motor cortex receives a major cholinergic
input from the Nucleus Basalis of Meynert, one of the most
aﬀected brain areas. TMS was employed to study the motor
cortex of AD patients demonstrating presence of subclinical
motor output reorganization from the early stages of the
disease [5]. Comparison with age- and gender-matched
controls showed, in the AD patients, increased motor cortex
excitability and frontal shift of the cortical motor maps for
hand and forearm muscles (Figure 1). Speciﬁcally, while in
normal controls the center of gravity (CoG) of the motor
cortical output, correspondent to the TMS excitable scalp
sites, coincides with the site of maximal excitability, or “hot
spot”, [60], in AD patients the CoG showed a frontal and
medial shift, with no changes in the “hot spot” location6 International Journal of Alzheimer’s Disease
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Figure 3: AD: Alzheimer disease, ADM: Abductor Digiti Minimi
Muscle, ECD: Extensor Digitorum Communis Muscle, Hot-Spot:
scalp site of maximal excitability. This picture shows that the
coordinates of the map center of gravity compared to the hot-
spot appear on average signiﬁcantly diﬀerent in the two groups:
in controls the center of gravity matches with the hot spot and
is located in the center of the map. In patients there is a marked
frontal and medial shift of center of gravity compared to Hot-Spot.
(modiﬁed from [5]).
(Figures 2 and 3). Increased excitability and frontomedial
“migration” of the excitable motor areas could be explained
by neuronal reorganization, possibly including the dysreg-
ulation of the inhibitory frontal centers (the “suppressory”
motor cortex or area 4S) and their integration with the
distributed excitatory network subtending motor output.
The frontomesial migration of the CoG does not seem to be
due to gross tissue changes secondary to atrophy; were this
the case, in fact, the “hot-spot” would have also similarly
shifted, with no dissociation from the CoG of the map [5].
The motor cortex, for the above-mentioned reasons, seems
capable of “self-defensive” reorganization, leading to late
appearance of clinically evident symptoms. A more recent
evidence of an altered synaptic plasticity in AD has been
also demonstrated by Inghilleri and colleagues in 2006. They
applied brief trains of high-frequency rTMS to motor cortex
andrecordedMEPsfromthecontralateralhandmuscles.The
researchers observed a progressive increase in MEP size in
normal age-matched controls and opposite changes in AD
[42]. This ﬁnding was interpreted as an altered short-term
synaptic enhancement in excitatory circuits of the motor
cortex.
4. TMS As Potential Instrument for Differential
Diagnosisof Dementia
Recently Pierantozzi ([44], see also above) proposed the
ppTMS paradigm as a noninvasive and reproducible tool to
obtain an early diﬀerential diagnosis between cholinergic
(AD) and non-cholinergic forms of dementia (FTD); the au-
thors, in fact, observed a signiﬁcant loss of MEPs inhibition
at ISI 2-3ms in early-onset AD patients but not in FTD pa-
tients and they speculated that these changes may be asc-
ribed, at least in part, to an impaired endogenous cholinergic
transmission.
In this vein it was also demonstrated [32, 61, 62] that
SAI is normal in FTD and in most of patients with VaD
whereas it is reduced in AD and dementia with Lewy bodies
(DLB). All together these results seem interesting with a view
to ﬁnd a tool to early diﬀerentiate diﬀerent kind of dementia
but further studies are required to conﬁrm these data and to
introduce this approach in the daily clinical practice.
5. TMS to ImproveCognitivePerformance in
MCI andAD Patients
Inthelast5yearsrTMShasbeenproposedasapossibletreat-
ment to improve cognitive performance not only in normal
subjects but also in patients aﬀected by dementia in which it
may represent a useful tool for cognitive rehabilitation. Par-
ticularly on one hand it was demonstrated that rTMS induce
a transient improvement in the associative memory task in
normal subjects and that it is associated with recruitment of
right prefrontal and bilateral posterior cortical regions [63],
on the other hand further studies have demonstrated that
rTMS on dorsolateral prefrontal cortex improves naming
performance in mild AD patients and also in the advanced
stages of the disease [64, 65]. Moreover recently rTMS [66]
was applied to AD patients to assess the duration of its eﬀects
on language performance and it was found that a 4-week
daily real rTMS treatment is able to induce at least an 8-week
lasting eﬀect on the improved performance.
Bentwich and colleagues [67] combined rTMS (applied
on six diﬀerent brain regions) with cognitive training; they
recruited eight patients with probable AD, who were treated
formorethan2monthswithcholinesteraseinhibitors.These
patients were subjected to daily rTMS-cognitive training ses-
sions (5/week) for 6 weeks, followed by maintenance session
(2/week) for an additional 3 months. They demonstrated a
signiﬁcant improvement in Alzheimer Disease Assessment
Scale-Cognitive (ADAS-cog) and in Clinical Global Impres-
sion of Change (CGIC) after both 6 weeks and 4.5 months
of treatment. These ﬁndings represent direct evidences that
rTMS is helpful in restoring brain functions and could re-
ﬂect rTMS potential to recruit compensatory networks
that underlie the memory-encoding and other congnitive
processes [68].
6. Conclusions andFuturePerspectives
Initially developed to excite peripheral nerves, TMS was qui-
cklyrecognized asavaluabletool tononinvasively investigate
and even activate the cerebral cortex in several neuro-psy-
chiatric disorders, such as dementia; to date the all ﬁndings
available suggest that TMS is a valuable tool to study
the neurophysiological basis of cognitive disorders. TMSInternational Journal of Alzheimer’s Disease 7
furnished several interesting patho-physiological informa-
tion and, although the cholinergic deﬁcit seems to be the
most accepted hypothesis, recent results indicate that AD
should be considered as a complex neurodegenerative dis-
ease, involving diﬀerent neurotransmitter systems. The sub-
sequent discovery that repetitive TMS could have long-last-
ing eﬀects on cortical excitability spawned a broad interest in
the use of this technique and, despite the current outcomes
from initial trials include some conﬂicting results, initial evi-
dence supports the idea that rTMS might have some thera-
peutic value in AD. To date, few studies have been conducted
at the predementia stage and correlations between cortical
excitability and cognitive performance have not been clearly
addressed.
Finally as altered functional connectivity may precede
structural changes, an objective method for the investigation
of early functional changes in cortical connectivity might be
useful in the early diagnosis and followup of AD [69]. With
thisviewthecombineduseofTMSwithotherbrainmapping
techniqueswillgreatlyexpandthescientiﬁcpotentialofTMS
in basic neuroscience and clinical research and will provide
substantial new insights in the pathophysiology of neuro-
psychiatric diseases. In recent years, several commercially av-
ailable devices have been introduced that allow recording
electroencephalographic (EEG) responses to TMS of a given
scalp site with millisecond resolution. The latency, ampli-
tude, and scalp topography of such responses are conside-
red a reliably reﬂection of corticocortical connectivity and
functional state [14, 57, 70]. Combining TMS with EEG ena-
bles a noninvasive, ﬁnally direct, method to study cortical
excitability and connectivity that is intrinsic neural proper-
ties and the connections of thalamocortical circuits can be
explored without involve peripheral stimulation or requiring
the active engagement of subjects in a cognitive task. EEG-
TMS is a promising tool to better characterize the neuronal
circuits underlying cortical eﬀective connectivity and its
disruptioninAlzheimer’sdiseaseandotherkindofdementia
[69].
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